EMA Recommends Granting a Marketing Authorisation for Poherdy By Ogkologos - April 10, 2026 54 0 Facebook Twitter Google+ Pinterest WhatsApp It is a biosimilar of pertuzumab which was authorised in the EU in 2013 Source RELATED ARTICLESMORE FROM AUTHOR Low-Dose Pembrolizumab with Dose-Dense Chemotherapy Increases pCR as Neoadjuvant Treatment for Localised TNBC ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma MOST POPULAR For AYAs with Advanced Cancer, Study Finds Serious Communication Gaps about... April 15, 2025 Off Target: Investigating the Abscopal Effect as a Treatment for Cancer January 28, 2020 关于肺癌生物标志物检测应当了解的信息：专家问答 April 13, 2023 Distinct Patient, Tumour, Treatment Characteristics and a Different Pattern and Risk... March 10, 2025 Load more HOT NEWS How My Inherited Cancer Diagnosis Has Made Me a Better Oncologist FDA Approves Osimertinib as Adjuvant Therapy for NSCLC with EGFR Exon... Will Ponsegromab Be a Game Changer for Cancer Cachexia? Biweekly Cabazitaxel in Patients 65 Years or Older with mCRPC for...
